

Published in final edited form as:

European J Med Plants. ; 3(4): 603–615.

High-Throughput Screening to Identify Plant Derived Human LDH-A Inhibitors

S. Deiab¹, E. Mazzi¹, S. Messeha¹, N. Mack¹, and K. F. A. Soliman^{1,*}

¹College of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, Florida 32307, USA

Abstract

Aims—Lactate dehydrogenase (LDH)-A is highly expressed in diverse human malignant tumors, parallel to aggressive metastatic disease, resistance to radiation/chemotherapy and clinically poor outcome. Although this enzyme constitutes a plausible target in treatment of advanced cancer, there are few known LDH-A inhibitors.

Study Design—In this work, we utilized a high-throughput enzyme micro-array format to screen and evaluate > 900 commonly used medicinal plant extracts (0.00001-.5 mg/ml) for capacity to inhibit activity of recombinant full length human LDHA; EC .1.1.1.27.

Methodology—The protein sequence of purified enzyme was confirmed using 1D gel electrophoresis- MALDI-TOF-MS/MS, enzyme activity was validated by oxidation of NADH (500 μ M) and kinetic inhibition established in the presence of a known inhibitor (Oxalic Acid).

Results—Of the natural extracts tested, the lowest IC₅₀s [<0.001 mg/ml] were obtained by: Chinese Gallnut (*Melaphis chinensis gallnut*), Bladderwrack (*Fucus vesiculosus*), Kelp (*Laminaria Japonica*) and Babul (*Acacia Arabica*). Forty-six additional herbs contained significant LDH-A inhibitory properties with IC₅₀s [<0.07 mg/ml], some of which have common names of Arjun, Pipsissewa, Cinnamon, Pink Rose Buds/Petals, Wintergreen, Cat's Claw, Witch Hazel Root and Rhodiola Root.

Conclusion—These findings reflect relative potency by rank of commonly used herbs and plants that contain human LDH-A inhibitory properties. Future research will be required to isolate chemical constituents within these plants responsible for LDH-A inhibition and investigate potential therapeutic application.

© 2013 Deiab et al.;

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Corresponding author: karam.soliman@famuedu.

Authors' contributions

This work was carried out in collaboration between all authors. Author SD prepared the extracts, performed the preliminary screening and wrote the discussion and introduction. Authors EM, SM and NM corroborated screening results, established enzyme kinetics, inhibitor controls and protein identification validation. Author KFA was involved with planning studies, drafting manuscript and overseeing research. All authors read and approved the final manuscript.

CONSENT

This section is not applicable to this paper.

ETHICAL APPROVAL

This section is not applicable to this paper.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

Keywords

Lactic acid; Warburg; LDH-A; inhibitor; herbs; medicinal plants

1. INTRODUCTION

Human lactate dehydrogenase is a tetrameric enzyme [1] highly expressed in smooth muscle. The LDH subtype A is up-regulated in diverse tumor tissues [2] including lung [3], pheochromocytoma, paraganglioma [4], esophageal squamous cell carcinoma [5], breast [6], endometrial adenocarcinoma, ovarian cystadenocarcinoma [7], hereditary leiomyomatosis renal carcinoma [8] and colon carcinoma [9–11]. Unlike normal differentiated cells where lactate accumulation occurs anaerobically, cancer cells readily convert glucose into lactate aerobically, a phenomenon termed the Warburg effect [12]. Elevated protein expression or enzyme function of LDH-A is a contributor to not only accumulated lactate, but also aggressive tumor growth [13], advanced progression [14], metastasis [15–17], acidity [18], and subsequent resistance to radiation and chemotherapy [19–22]. LDH-A knockdown, or lowering the functional capacity of LDH-A can suppress tumor growth and metastasis [23], indicating that this enzyme could serve as a novel targeted cancer therapy strategy. In this study, we elucidate LDH-A inhibitory effects of commonly used medicinal herbal extracts from around the world.

2. METHODOLOGY

Hanks Balanced Salt Solution, (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES), iodoacetamide, DL-Dithiothreitol (DTT), ethanol, 96 well plates, general reagents and supplies were all purchased from Sigma Scientific (Sigma, St Louis MO), LDH-A was purchased from Abcam (Cambridge, MA). Natural products were provided by Frontier Natural Products Co-op (Norway, IA), Monterey Bay Spice Company (Watsonville, CA), Mountain Rose Herbs (Eugene, OR), Mayway Traditional Chinese Herbs (Oakland, California), Kalyx Natural Marketplace (Camden, NY), Futureceuticals (Momence, IL), organic fruit vegetable markets and Florida Food Products Inc. (Eustis, FL).

2.1 Herbal Extraction

Plant and herbal extracts were macerated, diced, chopped and homogenized in 100% ethanol at 50mg/ml. Samples were placed on a rocker shaker for 24 hours and stored in air tight containers at -20°C in the dark. All serial dilutions were made using a diluent consisting of HBSS with 10mM HEPES adjusted to a pH 7.4.

2.2 MALDI MS/MS Protein Identification

Recombinant full length Human LDHA (amino acids 1–332) with N terminal His tag; 352 amino acids with tag, MW 38.8 kDa: Enzyme Commission (EC) Number 1.1.1.27 (BRENDA | IUBMB) (Abcam, Cambridge, MA) was utilized. The protein was validated by proteomic analysis using Matrix Assisted Laser Desorption Ionization (MALDI) Mass Spec (MS/MS) and analyzed by Mascot ID. Briefly, pure enzyme was solubilized, denatured and subjected to 1 D SDS page gel electrophoresis using a 5–20% Tris-HCL gradient gel with a running buffer 25 mM Tris, 192 mM glycine, 0.1% SDS at 200 V for 35 minutes. High intensity bands for LDH-A at 38 KD were visualized with G-Biosciences' LabSafe GEL Blue™ stain, then excised, followed by in gel digestion of peptides with trypsin, followed by reduction/alkylation with DTT and iodoacetamide, respectively. Samples were analyzed using MALDI MS/MS (Applied Biosystems) and protein sequence identified by Mascot analysis.

2.3 LDH-A Activity

A continuous LDH-A assay was used to conduct high-throughput screening (HTS). Briefly, a buffer consisted of HBSS + calcium and magnesium pH adjusted to 7.0. LDH-A enzyme (final concentration .02 Units/ml) was added to treatments of tier one, with concentrations of .5 mg/ml. After addition of β -Nicotinamide Adenine Dinucleotide, Reduced Form Solution (β -NADH) (final working concentration of 500 μ M) a pre-reading @ 340nm was established and the reaction was started with a solution of substrate pyruvate (final concentration = 3mM).

2.4 High Throughput Design

A rapid screening model was used based on works previously described [24]. An enzyme micro-array format was adapted to where a 96 well plate contained a known concentration of enzyme, and treatments of equal concentration dissolved in buffered HBSS and β -NADH. After addition of the substrate (pyruvate) a curve for time dependent NADH oxidation was monitored continuously over 75 minutes @340nm. A first tier investigation was established at a final working concentration of 0.5 mg/ml for each herbal extract. All compounds that inhibited LDH-A with in the first tier screen below 50% of control, were then placed in a second tier (final concentration = 0.25 mg/ml), third tier (final concentration =0.1 mg/ml) and fourth tier (final concentrations with extended range at 0.006, 0.03 and 0.16 mg/ml). Extracts were ranked for potency, and the most potent were further evaluated over a minimum of 6 concentrations from 1mg/ml to less than 0.00001 mg/ml to establish an IC₅₀. The enzyme micro-array format was rapid, reproducible and repeatedly corroborated by a four-tier evaluation process.

2.5 Data Analysis

Statistical analysis was performed using Graph Pad Prism (version 3.0; Graph Pad Software Inc. San Diego, CA, USA) with significance of difference between the groups assessed using a one-way ANOVA, followed by Tukey post hoc means comparison test, a two way ANOVA or Student's t test. IC₅₀s were determined by regression analysis using Origin Software (OriginLab, Northampton, MA).

3. RESULTS AND DISCUSSION

Method validation was established by monitoring continuous NADH oxidation initiated by addition of the substrate pyruvic acid (3mM) in the presence of varying enzyme concentration/time (Fig. 1a)

A screening validation process was established using 0.02 U/ml LDH-A over 75 minutes (Fig. 1b) \pm a known inhibitor; oxalic acid (Fig. 1c). The data shows a slow but steady rate of reaction, resulting in time dependent O.D. decay over 65–70 minutes with high signal/noise ratio.

Although the enzyme used in this screening, was described as a recombinant full length Human LDHA (amino acids 1–332) with N terminal His tag; 352 amino acids with tag, MW 38.8 kDa: Enzyme Commission (EC) Number 1.1.1.27 (BRENDA | IUBMB) (Abcam, Cambridge, MA), we confirmed the identity of the enzyme using Matrix Assisted Laser Desorption Ionisation (MALDI) Mass Spec (MS/MS) and analysis by Mascot ID (Fig. 2). Fig. 2 (Top panel) shows the 1 D SDS page gel electrophoresis of the purified enzyme at three concentrations (right), along with a molecular marker standard (left). The gel band was excised, digested and analyzed by MSMS for peptide sequence and protein identify (Bottom Panel). The data showed a positive hit for human LDH-A with a 95% confidence interval for peptide/sequence mass.

A high throughput enzyme micro-array model was used in this work. Over 900 extracts of equal concentration (0.5 mg/ml) were dissolved in buffered HBSS and incubated with the enzyme, for 5 minutes prior to start of the reaction. After addition of the substrate, a curve for time dependent product formation was monitored continuously over 75 minutes. Fig. 3 represents the 75 minute reading taken from the original screening with values for each compound sorted according to inhibitory potency. Of the initially tested extracts, only 115 inhibited LDH-A within the first tier below 50% of control, denoted by red dotted line --- (Fig. 3). These plant extracts were then subject to a second tier screenings (final concentration = 0.25 mg/ml), third tier screenings (final concentration = 0.1 mg/ml) and fourth tier screenings (final concentrations with extended range at 0.006 to 0.16 mg/ml) to which regression analysis was used to calculate IC_{50} s.

Of the 115 retested, 46 extracts showed an $IC_{50} < 0.077$ mg/ml Table 1 as listed by potency rank. Full inhibitory dose response curves are shown for the top four inhibitors (Fig. 4).

Table 1 Human LDH-A inhibitors by potency. Extract IC_{50} s are listed by both mg/ml and μ g/ml for inhibiting NADH oxidation on .02U/ml of LDHA.

4. DISCUSSION

In this HTS study, we investigated the ethanol extract of 905 natural products to identify those with human LDH-A inhibitor properties. Our results show *Melaphis chinensis* gallnut, also known as *Rhus chinensis* (RC) nut, to be the most potent and within a therapeutic range. *Rhus chinensis* belongs to family Anacardiaceae and genus *Rhus*. This family, consists of 250 species found in China [25] and many other locations around the world. Numerous traditional Chinese herbalists recommend RC for ailments such as chronic cough due to lung deficiency, chronic diarrhea and for clearing toxins. Unfortunately, these claims are not based on scientific grounds, yet the interest in this herb continues to increase for its numerous scientifically based findings. There is an abundance of research on the biological and pharmacological benefits of RC. For example, it was shown to be very effective in harmful intestinal and periodontal bacterial growth inhibition by a mechanism mediated in parts by its constituent's gallic acid and gallotaninns [26–28]. As an antiviral, RC ethyl acetate extract has inhibitory effects against hepatitis carcinoma virus [29,30] and severe acute respiratory syndrome corona virus [30]. Penta-1,2,3,4,6-O-galloyl- β -D-glucose (PGG) isolated from RC shows promising hepatoprotective properties [31] and the anticancer effects of RC are believed to involve inhibition of dcd25A phosphatase activity [32] or gallic acid as one of the bioactive components in RC [26,33,34] which directly induces apoptosis in prostate cancer cells [35]. PGG was also shown by Huh et al, to be a constituent in RC with ability to inhibit angiogenesis and stimulate apoptosis [36]. In addition, PGG reduced cancer cell viability [37] as well as suppressed prostate cancer, bone metastasis [38] and caused cell cycle arrest at the G1 phase [39].

5. CONCLUSION

The findings in this study, while broad show that a number of natural products have the ability to inhibit LDH-A, which may adversely affect cancer cell survival. We present evidence for LDH-A inhibitory properties of a number of commonly used herbs and spices with previously reported anti-cancer properties including bladderwrack [40], kelp [41], cinnamon [42], cats claw bark [43], arjun [44], polygonum multiflorum [45] and witch hazel [46]. Future research will be required to evaluate if LDH-A inhibition is a contributing factor to tumoricidal or anti-proliferative properties of these herbs on diverse human cancer cells.

Acknowledgments

This research was supported by a grant from NIH NCRR RCMI program (G12RR 03020) and the National Institute on Minority Health and Health Disparities, NIH (8G12MD007582-28 and 1P20 MD006738-01).

References

1. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107:2037–42. [PubMed: 20133848]
2. Goldman RD, Kaplan NO, Hall TC. Lactic Dehydrogenase in Human Neoplastic Tissues. *Cancer research*. 1964; 24:389–99. [PubMed: 14147812]
3. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. *Lung Cancer*. 2010; 70:211–7. [PubMed: 20181407]
4. Fliedner SM, Kaludercic N, Jiang XS, Hansikova H, Hajkova Z, Sladkova J, et al. Warburg effect's manifestation in aggressive pheochromocytomas and paragangliomas: insights from a mouse cell model applied to human tumor tissue. *PloS one*. 2012; 7:e40949. [PubMed: 22859959]
5. Yao F, Zhao T, Zhong C, Zhu J, Zhao H. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2013; 34:25–31. [PubMed: 22961700]
6. Hussien R, Brooks GA. Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines. *Physiological genomics*. 2011; 43:255–64. [PubMed: 21177384]
7. Koukourakis MI, Kontomanolis E, Giatromanolaki A, Sivridis E, Liberis V. Serum and tissue LDH levels in patients with breast/gynaecological cancer and benign diseases. *Gynecologic and obstetric investigation*. 2009; 67:162–8. [PubMed: 19088479]
8. Yang Y, Valera VA, Padilla-Nash HM, Sourbier C, Vocke CD, Vira MA, et al. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. *Cancer genetics and cytogenetics*. 2010; 196:45–55. [PubMed: 19963135]
9. Nilsson LM, Forshell TZ, Rimpi S, Kreutzer C, Pretsch W, Bornkamm GW, et al. Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis. *PLoS genetics*. 2012; 8:e1002573. [PubMed: 22438825]
10. Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H, et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma. *British journal of cancer*. 2013; 108:170–8. [PubMed: 23321518]
11. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2011; 17:4892–900. [PubMed: 21632858]
12. Warburg O. On the origin of cancer cells. *Science*. 1956; 123:309–14. [PubMed: 13298683]
13. Giatromanolaki A, Sivridis E, Bechrakis NE, Willerding G, St Charitoudis G, Foerster MH, et al. Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2alpha and survival. *Clinical & experimental metastasis*. 2012; 29:11–7. [PubMed: 21984395]
14. Ashrafian H, O'Flaherty L, Adam J, Steeples V, Chung YL, East P, et al. Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis. *Cancer research*. 2010; 70:9153–65. [PubMed: 20978192]
15. Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, et al. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. *Pharmacogenomics*. 2007; 8:1705–13. [PubMed: 18086000]

16. Huang L, Zheng M, Zhou QM, Zhang MY, Jia WH, Yun JP, et al. Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. *Cancer*. 2011; 117:3363–73. [PubMed: 21319141]
17. Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, et al. Acidity generated by the tumor microenvironment drives local invasion. *Cancer research*. 2013; 73:1524–35. [PubMed: 23288510]
18. Kareva I, Hahnfeldt P. The emerging “hallmarks” of metabolic reprogramming and immune evasion: distinct or linked? *Cancer research*. 2013; 73:2737–42. [PubMed: 23423980]
19. Sattler UG, Meyer SS, Quennet V, Hoerner C, Knoerzer H, Fabian C, et al. Glycolytic metabolism and tumour response to fractionated irradiation. *Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology*. 2010; 94:102–9. [PubMed: 20036432]
20. Groussard C, Morel I, Chevanne M, Monnier M, Cillard J, Delamarche A. Free radical scavenging and antioxidant effects of lactate ion: an in vitro study. *Journal of applied physiology: respiratory, environmental and exercise physiology*. 2000; 89:169–75.
21. Sattler UG, Mueller-Klieser W. The anti-oxidant capacity of tumour glycolysis. *International journal of radiation biology*. 2009; 85:963–71. [PubMed: 19895273]
22. Plathow C, Weber WA. Tumor cell metabolism imaging. *Journal of nuclear medicine: official publication Society of Nuclear Medicine*. 2008; 49 (Suppl 2):43S–63S.
23. Sheng SL, Liu JJ, Dai YH, Sun XG, Xiong XP, Huang G. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. *The FEBS journal*. 2012; 279:3898–910. [PubMed: 22897481]
24. Mazzio E, Deiab S, Park K, Soliman K. High throughput Screening to Identify Natural Human Monoamine Oxidase B Inhibitors. *Phytotherapy research: PTR*. 2013; 27:818–28. [PubMed: 22887993]
25. Yi T, Miller AJ, Wen J. Phylogenetic and biogeographic diversification of *Rhus* (Anacardiaceae) in the Northern Hemisphere. *Molecular phylogenetics and evolution*. 2004; 33:861–79. [PubMed: 15522809]
26. Ahn YJ, Lee CO, Kweon JH, Ahn JW, Park JH. Growth-inhibitory effects of *Galla Rhois*-derived tannins on intestinal bacteria. *Journal of applied microbiology*. 1998; 84:439–43. [PubMed: 9721649]
27. Wu-Yuan CD, Chen CY, Wu RT. Gallotannins inhibit growth, water-insoluble glucan synthesis, and aggregation of mutans streptococci. *Journal of dental research*. 1988; 67:51–5. [PubMed: 11039045]
28. Kang MS, Oh JS, Kang IC, Hong SJ, Choi CH. Inhibitory effect of methyl gallate and gallic acid on oral bacteria. *J Microbiol*. 2008; 46:744–50. [PubMed: 19107406]
29. Duan D, Li Z, Luo H, Zhang W, Chen L, Xu X. Antiviral compounds from traditional Chinese medicines *Galla* Chinese as inhibitors of HCV NS3 protease. *Bioorganic & medicinal chemistry letters*. 2004; 14:6041–4. [PubMed: 15546725]
30. Yi L, Li Z, Yuan K, Qu X, Chen J, Wang G, et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. *Journal of virology*. 2004; 78:11334–9. [PubMed: 15452254]
31. An RB, Oh H, Kim YC. Phenolic constituents of *Galla Rhois* with hepatoprotective effects on tacrine- and nitrofurantoin-induced cytotoxicity in Hep G2 cells. *Biological & pharmaceutical bulletin*. 2005; 28:2155–7. [PubMed: 16272710]
32. Yang H, Zheng S, Meijer L, Li SM, Leclerc S, Yu LL, et al. Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2 kinase. *Journal of Zhejiang University. Science B*. 2005; 6:656–63. [PubMed: 15973768]
33. Bae EA, Han MJ, Kim NJ, Kim DH. Anti-*Helicobacter pylori* activity of herbal medicines. *Biological & pharmaceutical bulletin*. 1998; 21:990–2. [PubMed: 9781854]
34. Choi JG, Kang OH, Lee YS, Oh YC, Chae HS, Jang HJ, et al. Antibacterial activity of methyl gallate isolated from *Galla Rhois* or carvacrol combined with nalidixic acid against nalidixic acid resistant bacteria. *Molecules*. 2009; 14:1773–80. [PubMed: 19471197]

35. Russell LH Jr, Mazzio E, Badisa RB, Zhu ZP, Agharahimi M, Oriaku ET, et al. Autoxidation of gallic acid induces ROS-dependent death in human prostate cancer LNCaP cells. *Anticancer research*. 2012; 32:1595–602. [PubMed: 22593437]
36. Huh JE, Lee EO, Kim MS, Kang KS, Kim CH, Cha BC, et al. Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways. *Carcinogenesis*. 2005; 26:1436–45. [PubMed: 15845650]
37. Jaszewska E, Kosmider A, Kiss AK, Naruszewicz M. *Oenothera paradoxa* defatted seeds extract containing pentagalloylglucose and procyanidins potentiates the cytotoxicity of vincristine. *Journal of physiology and pharmacology: an official journal of the Polish Physiological Society*. 2010; 61:637–43. [PubMed: 21081808]
38. Kuo PT, Lin TP, Liu LC, Huang CH, Lin JK, Kao JY, et al. Penta-O-galloyl-beta-D-glucose suppresses prostate cancer bone metastasis by transcriptionally repressing EGF-induced MMP-9 expression. *Journal of agricultural and food chemistry*. 2009; 57:3331–9. [PubMed: 19320436]
39. Zhang J, Li L, Kim SH, Hagerman AE, Lu J. Anti-cancer, anti-diabetic and other pharmacologic and biological activities of penta-galloyl-glucose. *Pharmaceutical research*. 2009; 26:2066–80. [PubMed: 19575286]
40. Lee H, Kim JS, Kim E. Fucoidan from seaweed *Fucus vesiculosus* inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways. *PLoS one*. 2012; 7:e50624. [PubMed: 23226337]
41. Go H, Hwang HJ, Nam TJ. A glycoprotein from *Laminaria japonica* induces apoptosis in HT-29 colon cancer cells. *Toxicology in vitro: an international journal published in association with BIBRA*. 2010; 24:1546–53. [PubMed: 20615460]
42. Varker KA, Ansel A, Aukerman G, Carson WE. 3rd Review of complementary and alternative medicine and selected nutraceuticals: background for a pilot study on nutrigenomic intervention in patients with advanced cancer. *Alternative therapies in health and medicine*. 2012; 18:26–34. [PubMed: 22516882]
43. Pilarski R, Poczekaj-Kostrzewska M, Ciesiolka D, Szyfter K, Gulewicz K. Antiproliferative activity of various *Uncaria tomentosa* preparations on HL-60 promyelocytic leukemia cells. *Pharmacological reports: PR*. 2007; 59:565–72. [PubMed: 18048957]
44. Saxena M, Faridi U, Mishra R, Gupta MM, Darokar MP, Srivastava SK, et al. Cytotoxic agents from *Terminalia arjuna*. *Planta medica*. 2007; 73:1486–90. [PubMed: 18008199]
45. Chen HS, Liu Y, Lin LQ, Zhao JL, Zhang CP, Jin JC, et al. Anti-proliferative effect of an extract of the root of *Polygonum multiflorum* Thunb, on MCF-7 human breast cancer cells and the possible mechanisms. *Mol Med Rep*. 2011; 4:1313–9. [PubMed: 21874249]
46. Sanchez-Tena S, Fernandez-Cachon ML, Carreras A, Mateos-Martin ML, Costoya N, Moyer MP, et al. Hamamelitannin from witch hazel (*Hamamelis virginiana*) displays specific cytotoxic activity against colon cancer cells. *Journal of natural products*. 2012; 75:26–33. [PubMed: 22216935]




Fig. 1a.




Fig. 1b.

Inhibitor Control (Oxalic Acid) on human LDH-A Enzyme Activity




Fig. 1c.

Fig. 1.

Fig. 1a. Human LDH-A Activity-time and enzyme concentration dependent NADH oxidation in the presence of 3mM pyruvate. The data represent μM NADH reduced from 0–75 minutes (incubation at RT) and are presented as the Mean \pm S.E.M, n=4. Significance of difference for product formation between Time $_0$ vs Time $_{15-75}$ minutes were determined using a two-way ANOVA. * p< 0.05

Fig. 1b. Human LDH Activity at .02 Units/ml with time dependent NADH oxidation in the presence of 3mM pyruvate. The data represent μM NADH and are presented as the Mean \pm S.E.M, n=4. Significance of difference for product formation between Time $_0$ vs Time $_{75}$ minutes was determined using a one-way ANOVA followed by a Tukey post hoc test. * p<0 .05

Fig. 1c. Human LDH Activity – Inhibitor Control. The data represent % Enzyme Activity @ 75 Minutes and are presented as the Mean \pm S.E.M, n=4. Significance of difference for enzyme activity between the control and oxalic acid (0.9–11.3 mM) was determined using a one-way ANOVA followed by a Tukey post hoc test. * p<0 .05

Human LDH-A : 1D Gel Electrophoresis : MALDI -TOF MS MS





Fig. 2. Mascot results for protein identification by peptide mass fingerprinting of Human LDH-A tryptic digest analyzed by MALDI-TOF/TOF-MS

First Tier Screening of Herb Extracts @ .5mg/ml




Fig. 3.

A high-throughput enzyme experimental micro-array design. 905 extracts were evaluated for capacity to inhibit *Human* LDH-A. A first tier screening was conducted at a final working concentration of 0.5 mg/ml for each herbal extract. Enzyme activity was continuously monitored over a 75 min period. Extracts demonstrating an $IC_{50} < 0.5$ mg/ml (red dotted line ----) were screened through subsequent tier evaluations




Fig. 4. Most Potent Herbal Extract Inhibitors of *Human* LDH-A activity. The data represent LDH-A activity as % control in the presence or absence of extracts and are presented as Mean \pm S.E.M., n=4. IC₅₀ concentrations were established from a sigmoidal fit dose-response equation and significance of difference between the controls vs. treatment was determined using a one-way ANOVA followed by a Tukey post hoc test. * p<0.05

Table 1

Natural source aqueous extracts with human LDH-A inhibitory potency by rank

Rank	ID No.	Common ± Chinese Name	Scientific Name	IC 50 mg/ml	IC 50 µg/ml
1	M22	Wu Bei Zi	<i>Melaphis chinensis gallnut</i>	0.00009	0.09
4	B53	Babul Chall Bark	<i>Acacia arabica</i>	0.00075	0.75
2	F17	Bladderwrack	<i>Fucus vesiculosus</i>	0.00100	1.00
3	K06	Kelp Powder	<i>Laminaria Japonica</i>	0.00134	1.34
5	B13	Bayberry Root bark	<i>Morella cerifera</i>	0.00158	1.58
6	C8	CraneSbill Root	<i>Geranium maculatum</i>	0.00173	1.73
7	A78	Arjun	<i>Terminalia arjuna</i>	0.00183	1.83
8	P54	Ye Jiao Ten	<i>Polygonum multiflorum vine</i>	0.00288	2.88
9	P56	Mu Dan Pi	<i>Paeonia suffruticose root - bark</i>	0.00298	2.98
10	W2	Witch Hazel Root	<i>Hamamelis virginiana</i>	0.00321	3.21
11	P82	Pipsissewa	<i>Chimaphila umbellata</i>	0.00410	4.10
12	C82	Cinnamon powder	<i>Cinnamon powder</i>	0.00434	4.34
13	R19	Rose Buds and Petals Pink	<i>Rosa Rugosa Flower</i>	0.00478	4.78
14	C10	Cat Claw Bark	<i>Uncaria tomentosa</i>	0.00483	4.83
15	D10	Dryopteris Male Fern Rhizome	<i>Dryopteris crassirhizoma</i>	0.00636	6.36
16	R25	Rhodiola Root	<i>Rhodiola kirilowii</i>	0.00809	8.09
17	T30	Turkey Rhubarb	<i>Rheum palmatum</i>	0.00958	9.58
18	G26	Wintergreen	<i>Gaultheria procumbens</i>	0.01086	10.86
19	XT76	Longon Peel	<i>Dimocarpus longan</i>	0.01195	11.95
20	H12	Gloryvine Stem	<i>Sargentodoxa cuneata vine</i>	0.01260	12.60
21	M6	Meadowsweet Powder	<i>Filipendula ulmaria</i>	0.01566	15.66
22	N2	Neem Leaf	<i>Azadirachta indica</i>	0.01836	18.36
23	T25	Sang Ji Sheng	<i>Taxillus chinensis stem & leaf</i>	0.02060	20.60
24	C32	Cynomorium songaricum	<i>Cynomorium songaricum</i>	0.02150	21.50
25	P55	Chi Shao	<i>Paeonia Lactiflora</i>	0.02283	22.83
26	P83	Pygeum Bark	<i>Pygeum africanum</i>	0.02623	26.23
27	P8	Hu Zhang	<i>Polygonum cuspidatum rhizome</i>	0.02842	28.42
28	XT8	Green Tea	<i>Camellia sinensis</i>	0.02852	28.52
29	XT91	Longon stem	<i>Dimocarpus longan</i>	0.02973	29.73

Rank	ID No.	Common ± Chinese Name	Scientific Name	IC 50 mg/ml	IC 50 µg/ml
30	A1	Agrimony	<i>Agrimonia eupatoria</i>	0.03072	30.72
31	L46	Linden Leaf	<i>Tilia europaea</i>	0.03152	31.52
32	A63	Sha Ren Guang	<i>Amonum villosum fruit Shelled</i>	0.04040	40.40
33	W16	White Willow Bark	<i>Salix alba</i>	0.04108	41.08
34	W15	White Oak Bark	<i>Quercus alba</i>	0.04154	41.54
35	G40	Guarana Seed	<i>Paullinia cupana</i>	0.04253	42.53
36	S11	St Johns Wort	<i>St Johns Wort</i>	0.04408	44.08
37	L25	Lychee Pit	<i>Litchi chinensis seed</i>	0.04592	45.92
38	H4	Hawthorne Leaf and Flower	<i>Crataegus laevigata</i>	0.04790	47.90
39	P13	Bian u	<i>Polygonum aviculare herb</i>	0.05264	52.64
40	N1	Nutmeg	<i>Myristica fragans</i>	0.05811	58.11
41	S8	Saw Palmetto Berry	<i>Serenoa repens</i>	0.06608	66.08
42	M38	Maiden Hair Fern	<i>Adiantum capillus</i>	0.06847	68.47
43	T4	Truja twigs, c/s	<i>Thuja occidentalis Cupressaceae</i>	0.07676	76.76
44	P29	Wei Ling Cai	<i>Potentilla chinensis herb</i>	0.07772	77.72